RxSight Inc. (RXST)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?
RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook
RxSight NASDAQ: RXST reported preliminary second-quarter financial results and provided updates on its product pipeline following a newly announced strategic collaboration agreement with Alcon, with management pointing to both near-term commercial headwinds and longer-term opportunities in adjustable intraocular lenses.
RxSight: After Dropping To The Bottom, It's Time To Pick It Up
RxSight, Inc. exhibits quantitative similarities to other small caps that I have rated here on Seeking Alpha that strongly outperformed the market. RXST is an 'NCAV' opportunity, a company that sells for less than its current asset value even though management is putting the company back on the growth track. My thesis is grounded in historical patterns where cash-rich, loss-making small caps often resolve operational issues before exhausting reserves.
RxSight Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 208 | $2,139.54 | $1,149.2 | -$990.34 | -46.29% |
| BG Bart Gancher Intech Investment Management LLC | 10,533 | $265,958.25 | $58,563.48 | -$207,394.77 | -77.98% |
 Point72 Asset Management LP Point72 Asset Management LP | 733,307 | $7.64M | $4.06M | -$3.58M | -46.83% |
 Joseph Castro Nuveen LLC | 70,887 | $738,642.6 | $393,068.41 | -$345,574.19 | -46.79% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 48 | $295.68 | $268.56 | -$27.12 | -9.17% |
RxSight Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Craig Bijou B of A Securities | -17,793.59 | $100,000 | $97,864.77 | $2,135.23 | 2.14% |
RxSight Inc. (RXST) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has RxSight Inc. ever had a stock split?
RxSight Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Ronald Kurtz CEO | NASDAQ (NMS) Exchange | 78349D107 CUSIP |
| US Country | 461 Employees | - Last Dividend | - Last Split | 30 Jul 2021 IPO Date |
Overview
RxSight, Inc. stands out as a pivotal figure in the medical device industry, focusing principally on the vital phases of research, development, manufacturing, and global sales of innovative light adjustable intraocular lenses (LAL) used predominantly in cataract surgery. This commercial-stage company, exercising its operations both within the United States and internationally, carries the legacy of revolutionizing post-surgery vision enhancement for patients undergoing cataract procedures. Initially established under the name Calhoun Vision, Inc., the company transitioned to RxSight, Inc. in February 2017, marking a significant rebranding phase centered around its groundbreaking products and technologies. Since its incorporation in 1997, RxSight, Inc., with its corporate headquarters nestled in Aliso Viejo, California, has dedicatedly served the specialist needs of cataract doctors and their patients, striving to deliver tailored visual outcomes post-cataract surgery.
Products and Services
The comprehensive offerings of RxSight, Inc. are encapsulated within its signature RxSight system, a testament to the company's commitment to innovation and customized patient care in cataract surgery recovery.
- RxSight Light Adjustable Lens: At the core of the RxSight system lies the Light Adjustable Lens, a marvel of medical technology designed with a special photosensitive material. This cutting-edge lens uniquely stands out for its ability to change shape and power, thereby permitting post-operative adjustments to align with the patient’s visual needs. Such a feature empowers patients with the possibility of achieving optimally tailored visual outcomes, a significant leap forward from the conventional intraocular lenses.
- RxSight Light Delivery Device: Complementing the functionality of the Light Adjustable Lens is the RxSight Light Delivery Device, a sophisticated, office-based UV light treatment apparatus. Engineered to deliver UV light in a meticulously programmed pattern, this device is crucial for modifying the Light Adjustable Lens according to the specific visual correction required. The process encapsulates the essence of RxSight, Inc.'s innovation by enabling on-demand adjustments to the lens, thus facilitating the attainment of the desired vision post-cataract surgery.
